Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Transl Behav Med. 2018 Jan 29;8(1):59-70. doi: 10.1093/tbm/ibx063.
Cancer-related genetic and genomic testing (CGT) is changing cancer care by personalizing care options, leading to an era of precision medicine. Advances in and increased use of CGT add complexity to clinical communication. This landscape analysis assessed published reviews of communication issues related to CGT and discusses implications for practice and behavioral research. A comprehensive electronic literature search was conducted of peer-reviewed literature reviews on studies related to CGT communication published between January 2010 and January 2017, resulting in a final sample of 24 reviews. Reviews were categorized, with overlaps, into four domains across the genetic testing communication continuum. Reviews on CGT-related knowledge, attitudes, and perceptions (n = 8) found that despite substantial public interest, their knowledge and awareness remains low. Providers also reported insufficient knowledge and overall caution, particularly regarding direct-to-consumer (DTC) genetic testing. Reviews of decision-making about CGT and test uptake (n = 8) identified individual, interpersonal, and systems-level barriers to uptake. Reviews of patient-provider CGT communication (n = 8) revealed limited communication and little empirical research on outcomes of communication or efforts at improving clinical and family communication. There were mixed findings in reviews (n = 15) on the psychological and behavioral impact of CGT, and DTC testing particularly had little effect on behaviors. Taken together, there is very little extant research in CGT in minority and underserved communities. In order for scientific advances in CGT to translate into equitable, patient-centered care, behavioral research, including health literacy and communication, plays critical roles.
癌症相关的基因和基因组检测(CGT)通过个性化治疗选择改变了癌症护理模式,引领了精准医学时代的到来。CGT 的进步和广泛应用增加了临床沟通的复杂性。本分析性研究评估了有关 CGT 沟通问题的已发表综述,并讨论了对实践和行为研究的影响。我们对 2010 年 1 月至 2017 年 1 月间发表的与 CGT 沟通相关的同行评审文献综述进行了全面的电子文献检索,最终样本为 24 篇综述。综述被分类,重叠部分被归入遗传检测沟通连续体的四个领域。8 篇关于 CGT 相关知识、态度和认知的综述发现,尽管公众对此类检测的兴趣很大,但他们的知识和认识仍然很低。提供者还报告说他们的知识不足,整体上比较谨慎,特别是对于直接面向消费者(DTC)的基因检测。8 篇关于 CGT 决策和测试采用的综述确定了采用的个体、人际和系统层面的障碍。8 篇关于患者与提供者间 CGT 沟通的综述显示沟通有限,关于沟通结果或改善临床和家庭沟通的努力的实证研究很少。15 篇关于 CGT 对心理和行为影响的综述结果不一,DTC 检测对行为的影响很小。总的来说,CGT 在少数民族和服务不足的社区中几乎没有相关研究。为了使 CGT 的科学进步转化为公平、以患者为中心的护理,行为研究,包括健康素养和沟通,起着至关重要的作用。